Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Epilepsy Research Group is at the forefront of some potentially ground-breaking work with patients who have drug-resistant epilepsy. Epilepsy affects over 50 million people worldwide and nearly one in three people with epilepsy are resistant to current drugs.

In August 2018, LivaNova PLC launched a global registry to evaluate the use of its Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy.

The system consists of two implantable components: a programmable electronic pulse generator that is connected to a bipolar electrical lead, which sends mild pulses to stimulate the vagus nerve at regular intervals throughout the day.

This study will enroll up to 2,000 patients and follow them for five years. The analysis of the data from this large repository will help to evaluate the safety and effectiveness of this therapy, as well as clinical outcomes for patients.

The Oxford Epilepsy Research Group, led by Arjune Sen, enrolled the first patient in Europe to the trial, and has recruited the largest number of patients to the study so far, along with Child Neurology Consultants Austin, Dr Keough.

Child Neurology Consultants Austin, Dr. Keough​

 

Similar stories

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

Alexander Davies wins top UKRI Future Leaders Fellowship

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.

John Jacob wins clinical academic research partnership for brain cancer project

The Medical Research Council awarded Dr John Jacob upwards of £200,000 to fund a project on brain cancer modelling.